Clinical trials: Cardiotoxicity, open to volunteers
Anthracycline-induced Cardiotoxicity, Lymphoma
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
- Conditions
- Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
- Trial name
- SPARTACUS (NCT07572175)
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cancer, Anticancer Treatment
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
Cancer management has undergone major advances over the past 30 years. Several anticancer therapies are now highly effective, allowing many cancers to become chronic diseases through sequential lines of treatment.
- Conditions
- Cancer, Anticancer Treatment, Cardiovascular Disease Risk Factor, Cardiovascular Diseases
- Trial name
- EUCARTOXSCORES (NCT07621289)
- Testing
- antineoplastic agents, endocrine therapy, immunostimulants drugs (ATC classification)
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Caen
Cardiotoxicity, Pulmonary Toxicity
Study on Proton Radiotherapy of Thymic Malignancies
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e.
- Conditions
- Cardiotoxicity, Pulmonary Toxicity, Thymus Neoplasms
- Trial name
- PROTHYM (NCT04822077)
- Testing
- Proton radiation
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Ass. Prof. Jan Nyman
Cardiotoxicity, Breast Cancer
NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity
Trastuzumab-induced cardiotoxicity (TIC) will be monitored in patients with HER2+ breast cancer undergoing trastuzumab treatment before and after breast cancer surgery.
- Conditions
- Cardiotoxicity, Breast Cancer, Treatment Side Effects
- Trial name
- NCT06340516
- Testing
- Plasma NT-proBNP
- Where
- Sweden
- Volunteers
- 700 people
- Sponsor
- Vastra Gotaland Region
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Cancer, Chemotherapeutic Toxicity
Serial PET MPI in Patients Undergoing Cancer Treatment
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.
- Conditions
- Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
- Trial name
- NCT05913999
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Breast Carcinoma, Head and Neck Cancer
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer
This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer.
- Conditions
- Breast Carcinoma, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT05787834
- Testing
- Best Practice, Medical Device Usage and Evaluation, Respiratory Muscle Training
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Roswell Park Cancer Institute
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
- Trial name
- NCT06353191
- Testing
- Non-Interventional Study
- Where
- 4 sites in United States
- Volunteers
- 693 people
- Sponsor
- Mayo Clinic
Cancer;Cardiovascular;Adverse Events, Cancer
Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies
This study will prospectively monitor cancer patients receiving chemotherapy (including molecular targeted therapies) for cardiovascular adverse events using biomarkers and imaging.
- Trial name
- NCT07058454
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Breast Cancer Females
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of…
- Trial name
- STRIVE (Acute) (NCT06781762)
- Testing
- N/A (Usual Care)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Breast Cancer, Metastatic Breast Cancer
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity
- Trial name
- NARNIA (NCT05732051)
- Testing
- Nicotinamide Riboside
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus
Cardiac Toxicity, Cancer
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.
- Trial name
- CV_CANCER (NCT06664528)
- Testing
- ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiotoxicity, Cardiac Biomarkers
Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)
Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. Blood tests such as cardiac troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can help clinicians investigate possible heart injury, but…
- Conditions
- Cardiotoxicity, Cardiac Biomarkers, Cancer
- Trial name
- PRIME-ICI (NCT07864727)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Cardiac Toxicity, Early-stage Breast Cancer
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
- Trial name
- NCT05559164
- Testing
- Lipitor 40mg Tablet
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Aluminum Phosphide Poisoning
Assessment of The Potential Therapeutic Effects of Trimetazidine on Aluminium Phosphide-Induced Cardiotoxicity as an Adjuvant Therapy: A Pilot Study
This study is designed as a pilot randomized controlled trial to investigate the potential role of trimetazidine (TMZ) as an adjuvant therapy in patients with acute Aluminum phosphide poisoning.
- Trial name
- NCT07916922
- Testing
- Trimetazidine, Standard Treatment
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Ain Shams University
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Breast Cancer
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines.
- Trial name
- SPRINT (NCT07070765)
- Testing
- Sodium-glucose transport-2 (SGLT-2) inhibitors, Standard medical treatment
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Aberdeen
Newly Diagnosed Acute Myeloid Leukemia (AML)
Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients
The aim of this study is to evaluate and compare the cardiotoxic effects associated with anthracycline-based induction chemotherapy and those receiving a Venetoclax or HMA regimens after four cycles of chemotherpy in patients…
- Trial name
- AML/HMA (NCT07851012)
- Volunteers
- 146 people
- Sponsor
- Assiut University
Non Small Cell Lung Cancer, Cardiotoxicity
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Trial name
- NCT07761910
- Testing
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Cardiotoxicity, Pediatric Cancer
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity.
- Conditions
- Cardiotoxicity, Pediatric Cancer, Heart Failure
- Trial name
- CATCH-HF (NCT04262830)
- Testing
- Cardiac magnetic resonance imaging (MRI), Accelerometer physical activity monitoring
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Hari Narayan